Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)

Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have shown variability in survival outcomes when used to treat peritoneal surface disease (PSD) from appendiceal and colorectal cancers. The primary goal of this study was to examine outcomes for high-grade appendiceal...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of gastrointestinal oncology 2016-02, Vol.7 (1), p.3-9
Hauptverfasser: Cummins, Kathleen A, Russell, Gregory B, Votanopoulos, Konstantinos I, Shen, Perry, Stewart, John H, Levine, Edward A
Format: Artikel
Sprache:eng
Schlagworte:
Original
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 9
container_issue 1
container_start_page 3
container_title Journal of gastrointestinal oncology
container_volume 7
creator Cummins, Kathleen A
Russell, Gregory B
Votanopoulos, Konstantinos I
Shen, Perry
Stewart, John H
Levine, Edward A
description Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have shown variability in survival outcomes when used to treat peritoneal surface disease (PSD) from appendiceal and colorectal cancers. The primary goal of this study was to examine outcomes for high-grade appendiceal (HGA) and high-grade colonic primaries after CRS-HIPEC to determine if a significant difference exists between the two groups. A retrospective analysis of patients with peritoneal dissemination from appendiceal and colonic primaries were identified in a prospectively maintained database of 1,223 CRS-HIPEC procedures performed between 1991 and 2015. Patient demographics, performance status resection status, tumor grade, nodal status, morbidity, mortality, and survival were reviewed with biopsy-proven PSD being classified according to primary site. Univariate and multivariate analyses were performed, and outcomes compared. The study identified 171 CRS-HIPEC procedures for 165 patients: 110 (66.7%) for HGA and 55 (33.3%) for high-grade colonic lesions. Observed median disease-free survival (DFS) and overall survival (OS) for both groups were the same at14.4 and 18 months, respectively. Median survival according to resection status for R0/R1, R2a, and R2b/c were 36, 15.6, and 8.4 months (P
doi_str_mv 10.3978/j.issn.2078-6891.2015.101
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4754307</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1770883718</sourcerecordid><originalsourceid>FETCH-LOGICAL-p266t-771544265894fbd7545df05114908861587e5b1bdd5ae4c16a4f561e321f63f43</originalsourceid><addsrcrecordid>eNpVUV1LHTEUDEVRsf4FSd_0Ya-b3XxsXgS5WBUExbbQtyU3OXs3spusSVa5f6W_1lzU1p6XMzBzZgYOQt9IuailaM4eFzZGt6hK0RS8kSQjwhakJF_QQVURWXAhf-9k_CHYR0cxPpZ5qGQlq_bQfsUlJVLIA_TnHoJN3oEasMnGMFqnkvUOd8GPuLfrvlgHZQCraQJnrN4qtXIaAk4BVAKDX2zqsd4kH8DMOtlnwHEOawgbfLJ8-HGKlTO430wQUg9htBpbl4Ka_kXrHka_JdWUb65v7i-Xp1_RbqeGCEfv-xD9-n75c3ld3N5d3Swvboup4jwVQhBGacVZI2m3MoJRZrqSEUJl2TScsEYAW5GVMUwB1YQr2jFOoK5Ix-uO1ofo_M13mlcjGA3bbkM7BTuqsGm9su3_jLN9u_bPLc1ZdSmywcm7QfBPM8TUjjZqGAblwM-xJULkJrUgTZYef876G_LxkPoV25uUtQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1770883718</pqid></control><display><type>article</type><title>Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Cummins, Kathleen A ; Russell, Gregory B ; Votanopoulos, Konstantinos I ; Shen, Perry ; Stewart, John H ; Levine, Edward A</creator><creatorcontrib>Cummins, Kathleen A ; Russell, Gregory B ; Votanopoulos, Konstantinos I ; Shen, Perry ; Stewart, John H ; Levine, Edward A</creatorcontrib><description>Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have shown variability in survival outcomes when used to treat peritoneal surface disease (PSD) from appendiceal and colorectal cancers. The primary goal of this study was to examine outcomes for high-grade appendiceal (HGA) and high-grade colonic primaries after CRS-HIPEC to determine if a significant difference exists between the two groups. A retrospective analysis of patients with peritoneal dissemination from appendiceal and colonic primaries were identified in a prospectively maintained database of 1,223 CRS-HIPEC procedures performed between 1991 and 2015. Patient demographics, performance status resection status, tumor grade, nodal status, morbidity, mortality, and survival were reviewed with biopsy-proven PSD being classified according to primary site. Univariate and multivariate analyses were performed, and outcomes compared. The study identified 171 CRS-HIPEC procedures for 165 patients: 110 (66.7%) for HGA and 55 (33.3%) for high-grade colonic lesions. Observed median disease-free survival (DFS) and overall survival (OS) for both groups were the same at14.4 and 18 months, respectively. Median survival according to resection status for R0/R1, R2a, and R2b/c were 36, 15.6, and 8.4 months (P&lt;0.0001). Median OS for those who received preoperative chemotherapy versus those who did not were 14.4 and 20.4 months, respectively (P=0.01). For those who received preoperative chemotherapy, no difference was apparent in the DFS interval (P=0.34). Multivariate predictors of OS included resection status (P&lt;0.0001) and lymph node involvement (P=0.0005). Preoperative chemotherapy offered no clear DFS or OS benefit, for HGA or high-grade colon cancer patients. Complete cytoreduction offered the greatest survival benefit to both groups with a correlating drop in survival to resection status. Outcomes for high grade appendiceal cancer are remarkably similar to colon cancer.</description><identifier>ISSN: 2078-6891</identifier><identifier>EISSN: 2219-679X</identifier><identifier>DOI: 10.3978/j.issn.2078-6891.2015.101</identifier><identifier>PMID: 26941979</identifier><language>eng</language><publisher>China: AME Publishing Company</publisher><subject>Original</subject><ispartof>Journal of gastrointestinal oncology, 2016-02, Vol.7 (1), p.3-9</ispartof><rights>2016 Journal of Gastrointestinal Oncology. All rights reserved. 2016 Journal of Gastrointestinal Oncology.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754307/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754307/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26941979$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cummins, Kathleen A</creatorcontrib><creatorcontrib>Russell, Gregory B</creatorcontrib><creatorcontrib>Votanopoulos, Konstantinos I</creatorcontrib><creatorcontrib>Shen, Perry</creatorcontrib><creatorcontrib>Stewart, John H</creatorcontrib><creatorcontrib>Levine, Edward A</creatorcontrib><title>Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)</title><title>Journal of gastrointestinal oncology</title><addtitle>J Gastrointest Oncol</addtitle><description>Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have shown variability in survival outcomes when used to treat peritoneal surface disease (PSD) from appendiceal and colorectal cancers. The primary goal of this study was to examine outcomes for high-grade appendiceal (HGA) and high-grade colonic primaries after CRS-HIPEC to determine if a significant difference exists between the two groups. A retrospective analysis of patients with peritoneal dissemination from appendiceal and colonic primaries were identified in a prospectively maintained database of 1,223 CRS-HIPEC procedures performed between 1991 and 2015. Patient demographics, performance status resection status, tumor grade, nodal status, morbidity, mortality, and survival were reviewed with biopsy-proven PSD being classified according to primary site. Univariate and multivariate analyses were performed, and outcomes compared. The study identified 171 CRS-HIPEC procedures for 165 patients: 110 (66.7%) for HGA and 55 (33.3%) for high-grade colonic lesions. Observed median disease-free survival (DFS) and overall survival (OS) for both groups were the same at14.4 and 18 months, respectively. Median survival according to resection status for R0/R1, R2a, and R2b/c were 36, 15.6, and 8.4 months (P&lt;0.0001). Median OS for those who received preoperative chemotherapy versus those who did not were 14.4 and 20.4 months, respectively (P=0.01). For those who received preoperative chemotherapy, no difference was apparent in the DFS interval (P=0.34). Multivariate predictors of OS included resection status (P&lt;0.0001) and lymph node involvement (P=0.0005). Preoperative chemotherapy offered no clear DFS or OS benefit, for HGA or high-grade colon cancer patients. Complete cytoreduction offered the greatest survival benefit to both groups with a correlating drop in survival to resection status. Outcomes for high grade appendiceal cancer are remarkably similar to colon cancer.</description><subject>Original</subject><issn>2078-6891</issn><issn>2219-679X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNpVUV1LHTEUDEVRsf4FSd_0Ya-b3XxsXgS5WBUExbbQtyU3OXs3spusSVa5f6W_1lzU1p6XMzBzZgYOQt9IuailaM4eFzZGt6hK0RS8kSQjwhakJF_QQVURWXAhf-9k_CHYR0cxPpZ5qGQlq_bQfsUlJVLIA_TnHoJN3oEasMnGMFqnkvUOd8GPuLfrvlgHZQCraQJnrN4qtXIaAk4BVAKDX2zqsd4kH8DMOtlnwHEOawgbfLJ8-HGKlTO430wQUg9htBpbl4Ka_kXrHka_JdWUb65v7i-Xp1_RbqeGCEfv-xD9-n75c3ld3N5d3Swvboup4jwVQhBGacVZI2m3MoJRZrqSEUJl2TScsEYAW5GVMUwB1YQr2jFOoK5Ix-uO1ofo_M13mlcjGA3bbkM7BTuqsGm9su3_jLN9u_bPLc1ZdSmywcm7QfBPM8TUjjZqGAblwM-xJULkJrUgTZYef876G_LxkPoV25uUtQ</recordid><startdate>20160201</startdate><enddate>20160201</enddate><creator>Cummins, Kathleen A</creator><creator>Russell, Gregory B</creator><creator>Votanopoulos, Konstantinos I</creator><creator>Shen, Perry</creator><creator>Stewart, John H</creator><creator>Levine, Edward A</creator><general>AME Publishing Company</general><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160201</creationdate><title>Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)</title><author>Cummins, Kathleen A ; Russell, Gregory B ; Votanopoulos, Konstantinos I ; Shen, Perry ; Stewart, John H ; Levine, Edward A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p266t-771544265894fbd7545df05114908861587e5b1bdd5ae4c16a4f561e321f63f43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Original</topic><toplevel>online_resources</toplevel><creatorcontrib>Cummins, Kathleen A</creatorcontrib><creatorcontrib>Russell, Gregory B</creatorcontrib><creatorcontrib>Votanopoulos, Konstantinos I</creatorcontrib><creatorcontrib>Shen, Perry</creatorcontrib><creatorcontrib>Stewart, John H</creatorcontrib><creatorcontrib>Levine, Edward A</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of gastrointestinal oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cummins, Kathleen A</au><au>Russell, Gregory B</au><au>Votanopoulos, Konstantinos I</au><au>Shen, Perry</au><au>Stewart, John H</au><au>Levine, Edward A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)</atitle><jtitle>Journal of gastrointestinal oncology</jtitle><addtitle>J Gastrointest Oncol</addtitle><date>2016-02-01</date><risdate>2016</risdate><volume>7</volume><issue>1</issue><spage>3</spage><epage>9</epage><pages>3-9</pages><issn>2078-6891</issn><eissn>2219-679X</eissn><abstract>Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have shown variability in survival outcomes when used to treat peritoneal surface disease (PSD) from appendiceal and colorectal cancers. The primary goal of this study was to examine outcomes for high-grade appendiceal (HGA) and high-grade colonic primaries after CRS-HIPEC to determine if a significant difference exists between the two groups. A retrospective analysis of patients with peritoneal dissemination from appendiceal and colonic primaries were identified in a prospectively maintained database of 1,223 CRS-HIPEC procedures performed between 1991 and 2015. Patient demographics, performance status resection status, tumor grade, nodal status, morbidity, mortality, and survival were reviewed with biopsy-proven PSD being classified according to primary site. Univariate and multivariate analyses were performed, and outcomes compared. The study identified 171 CRS-HIPEC procedures for 165 patients: 110 (66.7%) for HGA and 55 (33.3%) for high-grade colonic lesions. Observed median disease-free survival (DFS) and overall survival (OS) for both groups were the same at14.4 and 18 months, respectively. Median survival according to resection status for R0/R1, R2a, and R2b/c were 36, 15.6, and 8.4 months (P&lt;0.0001). Median OS for those who received preoperative chemotherapy versus those who did not were 14.4 and 20.4 months, respectively (P=0.01). For those who received preoperative chemotherapy, no difference was apparent in the DFS interval (P=0.34). Multivariate predictors of OS included resection status (P&lt;0.0001) and lymph node involvement (P=0.0005). Preoperative chemotherapy offered no clear DFS or OS benefit, for HGA or high-grade colon cancer patients. Complete cytoreduction offered the greatest survival benefit to both groups with a correlating drop in survival to resection status. Outcomes for high grade appendiceal cancer are remarkably similar to colon cancer.</abstract><cop>China</cop><pub>AME Publishing Company</pub><pmid>26941979</pmid><doi>10.3978/j.issn.2078-6891.2015.101</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 2078-6891
ispartof Journal of gastrointestinal oncology, 2016-02, Vol.7 (1), p.3-9
issn 2078-6891
2219-679X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4754307
source EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Original
title Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T01%3A41%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Peritoneal%20dissemination%20from%20high-grade%20appendiceal%20cancer%20treated%20with%20cytoreductive%20surgery%20(CRS)%20and%20hyperthermic%20intraperitoneal%20chemotherapy%20(HIPEC)&rft.jtitle=Journal%20of%20gastrointestinal%20oncology&rft.au=Cummins,%20Kathleen%20A&rft.date=2016-02-01&rft.volume=7&rft.issue=1&rft.spage=3&rft.epage=9&rft.pages=3-9&rft.issn=2078-6891&rft.eissn=2219-679X&rft_id=info:doi/10.3978/j.issn.2078-6891.2015.101&rft_dat=%3Cproquest_pubme%3E1770883718%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1770883718&rft_id=info:pmid/26941979&rfr_iscdi=true